| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | FORM S-8 |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the se... |
| 30 Oct 2026 |
Form 4: Payton Lori, Chief Development Officer
Granted 99,827 Stock Option (Right to Buy) |
| 30 Oct 2026 |
Form 4: Alford Rachael, Chief Operating Officer
Granted 89,844 Stock Option (Right to Buy) |
| 30 Oct 2026 |
Form 4: Frey Rebecca, Director
Granted 465,857 Stock Option (Right to Buy) |
| 30 Oct 2026 |
Form 4: Ryder Steven, Chief Medical Officer
Granted 113,137 Stock Option (Right to Buy) |
| 30 Oct 2026 |
Form 4: Zeronda Tyler, Chief Financial Officer
Granted 156,115 Stock Option (Right to Buy) |
| 07 Oct 2026 | SCHEDULE 13G |
| 17 Sep 2026 | SCHEDULE 13G |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,769,231 shares of its common stock, par valu... |
| 11 Sep 2026 | 424B5 |
| 11 Sep 2026 | 424B5 |
| 10 Sep 2026 |
8-K: Other Events
Yarrow Bioscience, Inc. (“Yarrow”) is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Yarrow’s lead product candidate, YB-101 (also known as GenSci098), is a humanize... |
| 19 Aug 2026 | EFFECT |
| 14 Aug 2026 | SCHEDULE 13G |
Loading...